Summary of COVID-19 mefenamic acid studies
Hide extended summaries
36 patient mefenamic acid early treatment RCT: 94% improved recovery (p=0.03).
RCT 36 COVID-19 outpatients showing reduced time to an "acceptable symptom state" with mefenamic acid treatment, however the effect was driven by pain-related symptoms and is likely, at least in part, due to mefenamic acid’s analgesic action.
Jan 2022, Int. J. Molecular Medicine, http://www.spandidos-publications.com/10.3892/ijmm.2022.5084, https://c19p.org/guzmanesquivel
36 patient mefenamic acid early treatment RCT: 94% improved recovery (p=0.03).
RCT 36 COVID-19 outpatients showing reduced time to an "acceptable symptom state" with mefenamic acid treatment, however the effect was driven by pain-related symptoms and is likely, at least in part, due to mefenamic acid’s analgesic action.
Jan 2022, Int. J. Molecular Medicine, http://www.spandidos-publications.com/10.3892/ijmm.2022.5084, https://c19p.org/guzmanesquivel
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.